BD to Invest $3B in US Manufacturing, Including $1B in Nebraska
BDX sits 42% above its 52-week low of $127.536.
Summary
President Trump announced that Becton Dickinson will invest $3 billion to expand US manufacturing of essential medical products, with over $1 billion earmarked for Nebraska to ramp up production of needles made with American steel. The company has not yet commented. This is a significant capital commitment that aligns with the administration's push for domestic medical supply chain resilience. The investment follows BD's recent spin-off of its Biosciences & Diagnostic Solutions business and ongoing share buyback programs, suggesting a strategic pivot toward onshoring core manufacturing. The announcement could signal increased US government support or contracts for BD, though details on timing and funding are not yet disclosed.
At the time of this announcement, BDX was trading at $180.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $49.2B. The 52-week trading range was $127.54 to $193.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.